|
|
| | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate Basic information |
| Product Name: | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate | | Synonyms: | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate;(1R,2S,5R)-2-[5-(3-Azetidinyl)-1,3,4-oxadiazol2-yl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-ylhydrogen sulfate;β-Lactamase-IN-4;Sulfuric acid, mono[(1R,2S,5R)-2-[5-(3-azetidinyl)-1,3,4-oxadiazol-2-yl]-7-oxo-1,6-diazabicyclo[3.2.1]oct-6-yl] ester | | CAS: | 1463520-91-3 | | MF: | C11H15N5O6S | | MW: | 345.33 | | EINECS: | | | Product Categories: | | | Mol File: | 1463520-91-3.mol | ![(2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate Structure](CAS/20210305/GIF/1463520-91-3.gif) |
| | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate Chemical Properties |
| density | 1.80±0.1 g/cm3(Predicted) | | pka | -4.59±0.18(Predicted) |
| | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate Usage And Synthesis |
| Uses | β-Lactamase-IN-4 is a β-lactamase inhibitor extracted from patent WO2013149121A1, compound 708. β-Lactamase-IN-4 can be used for the research of bacterial infections[1]. | | References | [1] Gu YG, et, al. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors. WO2013149121A1. |
| | (2S,5R)-2-(5-(azetidin-3-yl)-1,3,4-oxadiazol-2-yl)-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate Preparation Products And Raw materials |
|